Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Tools
- Tools
+ Tools

Zalcberg, J. R., Verweij, J., Casali, P. G., Le Cesne, A., Reichardt, P., Blay, J. Y., Schlemmer, M., Van Glabbeke, M., Brown, M., Judson, I. R. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. EUROPEAN JOURNAL OF CANCER, 41 (12). pp. 1751-1757. ISSN 0959-8049

Full text not available from this repository.

Abstract

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumours (GIST) were randomised to receive 400 or 800 mg of imatinib daily. An increase in progression free survival (PFS) was demonstrated for patients randomised to the high-dose arm. Patients randomised to low-dose could cross-over to high-dose upon progression. We evaluated the feasibility, safety and efficacy of this policy. Of the 241 patients available for follow-up, 133 patients (55%) crossed over to high-dose imatinib according to the protocol. Of these patients, 92% had not had a prior dose reduction. The cumulative incidence of subsequent dose reductions after cross-over was 17% after six months with 51% discontinuing therapy without requiring a dose reduction. The extent of anaemia and fatigue increased significantly after cross-over, whilst neutropenia was less severe than during low-dose treatment. Objective responses after cross-over included three patients (2%) with a partial response and 36 (27%) with stable disease. The median PFS after cross-over was 81 days, although 18.1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy. (C) 2005 Elsevier Ltd. All rights reserved.

Item Type: Article
Authors (ICR Faculty only): Judson, Ian
All Authors: Zalcberg, J. R., Verweij, J., Casali, P. G., Le Cesne, A., Reichardt, P., Blay, J. Y., Schlemmer, M., Van Glabbeke, M., Brown, M., Judson, I. R.
Uncontrolled Keywords: imatinib; GIST; dose effects; progression Anticancer agents; phase-ii; trial; efficacy; mesylate; safety
Research teams: Clinical Units > Sarcoma Unit
ICR divisions > Cancer Therapeutics > Signal Transduction & Molecular Pharmacology
Depositing User: EPrints Services
Date Deposited: 10 Aug 2007 20:52
Last Modified: 23 Apr 2015 15:12
URI: http://publications.icr.ac.uk/id/eprint/2299

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust